Skip to Content

Drug-Induced Autoimmunity

By

Jennifer M. Barker

, MD, Children's Hospital Colorado, Division of Pediatric Endocrinology

Last full review/revision Apr 2021| Content last modified Apr 2021

Patients receiving drugs in the novel class of cancer therapeutics called immune checkpoint inhibitors, have an increased risk for development of autoimmune disorders, including endocrine disorders. Hypophysitis, autoimmune thyroid disease (both hyperthyroidism and hypothyroidism), type 1 diabetes, and primary adrenal insufficiency have been reported (1, 2).

Diagnosis is by measurement of levels of glucose, electrolytes, and hormones as clinically indicated.

Treatment is replacement of hormones documented to be deficient. These might include thyroid hormone, insulin, or glucocorticoids.

General references

  • 1. Ruggeri RM, Campennì A, Giuffrida G, et al: Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest Nov. 23, 2018. https://doi.org/10.1007/s40618-018-0984-z
  • 2. Chang L-S, Barroso-Sousa R, Tolaney SM, et al: Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40(1):17–65, 2019. doi: 10.1210/er.2018-00006

Copyright © 2021 Merck & Co., Inc., known as MSD outside of the US, Kenilworth, New Jersey, USA. All rights reserved. Merck Manual Disclaimer